Treatment of anemia of low risk myelodysplastic syndrome (FDA approval of Luspatercept in LR-MDS)
Treatment of anemia of low risk myelodysplastic syndrome (FDA approval of Luspatercept in LR-MDS)
14/11/2024 17:00
Speakers: Uwe Platzbecker
Target:
Health professionals
Subnetworks: Myeloid malignancies
Disease Groups: Myelodysplastic syndrome